These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 16914961

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH, Lyoussi B, Hernández-Hernández R, Velasco M.
    Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?
    Rayner B.
    Curr Med Res Opin; 2004 Mar; 20(3):359-67. PubMed ID: 15025845
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Angiotensin receptor blockers: Cardiovascular protection in the metabolic syndrome.
    Deedwania PC, Schmieder R.
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S12-8. PubMed ID: 16986230
    [Abstract] [Full Text] [Related]

  • 8. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB.
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [Abstract] [Full Text] [Related]

  • 9. The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension.
    Ruilope L, Kjeldsen SE, de la Sierra A, Mancia G, Ruggenenti P, Stergiou GS, Bakris GL, Giles TD.
    Blood Press; 2007 Mar; 16(2):72-9. PubMed ID: 17612904
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials.
    Haffner SM, Ruilope L, Dahlöf B, Abadie E, Kupfer S, Zannad F.
    J Cardiovasc Pharmacol; 2006 Mar; 47(3):469-75. PubMed ID: 16633092
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients.
    Vlek AL, van der Graaf Y, Spiering W, Visseren FL, SMART study group.
    J Hum Hypertens; 2008 May; 22(5):358-65. PubMed ID: 18273039
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antihypertensive therapy in the presence of proteinuria.
    Sarafidis PA, Khosla N, Bakris GL.
    Am J Kidney Dis; 2007 Jan; 49(1):12-26. PubMed ID: 17185142
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Improving cardiovascular health outcomes through the use of evidence-based medicine.
    Douglas J.
    Ethn Dis; 2005 Jan; 15(2 Suppl 2):S23-6. PubMed ID: 15822833
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.